Novartis Stock Lifted As Psoriasis Drug Notches EU Approval

Novartis Stock Lifted As Psoriasis Drug Notches EU Approval

Europe granted approval for Novartis drug Cosentyx in treating moderate-to-severe plaque psoriasis in patients age 6 to under 18, after successful Phase 3 testing, sending NVS stock rising.